

## Treatment continuation and satisfaction in women using combined oral contraception with norgestrel acetate and oestradiol: a multicentre, prospective cohort study (BOLERO)

Angelo Cagnacci, Carlo Bastianelli, Manuela Neri, Antonio Cianci, Chiara Benedetto, Luana Calanni, Michele Vignali, Vincenzo De Leo, Ettore Cicinelli, Giuseppe Borrelli, Annibale Volpe & ; The BOLERO Study Writing Group

To cite this article: Angelo Cagnacci, Carlo Bastianelli, Manuela Neri, Antonio Cianci, Chiara Benedetto, Luana Calanni, Michele Vignali, Vincenzo De Leo, Ettore Cicinelli, Giuseppe Borrelli, Annibale Volpe & ; The BOLERO Study Writing Group (2018) Treatment continuation and satisfaction in women using combined oral contraception with norgestrel acetate and oestradiol: a multicentre, prospective cohort study (BOLERO), *The European Journal of Contraception & Reproductive Health Care*, 23:6, 393-399, DOI: [10.1080/13625187.2018.1541080](https://doi.org/10.1080/13625187.2018.1541080)

To link to this article: <https://doi.org/10.1080/13625187.2018.1541080>



© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group



Published online: 22 Nov 2018.



Submit your article to this journal [↗](#)



Article views: 396



View Crossmark data [↗](#)

## Treatment continuation and satisfaction in women using combined oral contraception with nomegestrol acetate and oestradiol: a multicentre, prospective cohort study (BOLERO)

Angelo Cagnacci<sup>a</sup>, Carlo Bastianelli<sup>b</sup>, Manuela Neri<sup>c</sup>, Antonio Cianci<sup>d</sup>, Chiara Benedetto<sup>e</sup>, Luana Calanni<sup>f</sup>, Michele Vignali<sup>g</sup>, Vincenzo De Leo<sup>h</sup>, Ettore Cicinelli<sup>i</sup>, Giuseppe Borrelli<sup>j</sup> and Annibale Volpe<sup>k</sup>; The BOLERO Study Writing Group\*

<sup>a</sup>Clinica Ginecologica e Ostetrica, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy; <sup>b</sup>Dipartimento di Scienze Ostetriche e Ginecologiche e Scienze Urologiche, La Sapienza Università di Roma, Rome, Italy; <sup>c</sup>Clinica Ostetrica e Ginecologica, Dipartimento di Scienze Chirurgiche, Università degli Studi di Cagliari, Azienda Ospedaliero Universitaria di Cagliari, Policlinico Universitario Duilio Casula, Monserrato, Italy; <sup>d</sup>Dipartimento Chirurgia Generale e Specialità Medico Chirurgiche, Azienda Ospedaliero Universitaria Policlinico-Vittorio Emanuele, Catania, Italy; <sup>e</sup>Dipartimento di Scienze Chirurgiche, Università degli Studi di Torino, Turin, Italy; <sup>f</sup>Clinica Ostetrica e Ginecologia, Ospedale Policlinico San Martino, Genoa, Italy; <sup>g</sup>Dipartimento di Scienze Biomedicine per la Salute, Università degli Studi di Milano, Milan, Italy; <sup>h</sup>Dipartimento di Medicina Molecolare e dello Sviluppo, Azienda Ospedaliera Universitaria Senese, Siena, Italy; <sup>i</sup>2° Unità Operativa di Ginecologia ed Ostetricia, Dipartimento di Medicina e Oncologia (DIMO), Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy; <sup>j</sup>Teva Italia Srl, Assago, Italy; <sup>k</sup>Facoltà di Medicina e Chirurgia Materno-Infantili e dell'Adulto, Università degli Studi di Modena e Reggio Emilia, Modena, Italy

### ABSTRACT

**Objective:** The aim of the study was to examine treatment continuation and satisfaction over 1 year among women receiving nomegestrol acetate (NOMAC)/oestradiol (E2) combined oral contraception (COC) in real-world clinical practice.

**Methods:** The 17 $\beta$ -Estradiol and Nomegestrol Acetate (BOLERO) Study is an observational, non-interventional, prospective, multicentre cohort study of premenopausal women (aged 18–50 years) who received prescription NOMAC/E2 (2.5 mg/1.5 mg) for contraception during routine clinical practice. Assessments were carried out at enrolment and at 3, 6 and 12 months. Probability of treatment continuation through 12 months (primary outcome) was examined using Kaplan–Meier survival analysis. Secondary outcomes included treatment satisfaction, menstrual cycle-related symptoms, libido and adverse events (AEs).

**Results:** Of 298 enrolled women, 292 were evaluable. The probability of NOMAC/E2 continuation through 12 months was 73.7% (95% confidence interval [CI] 68.0%, 78.5%). Satisfaction with NOMAC/E2 increased from 56.9% (37/65) of women at initial evaluation to 89.2% (58/65) of women at 12 months. Physician ratings at 12 months showed satisfactory to very satisfactory in 84.0% (168/200) of women. Libido was not affected. Menstrual cycle-related symptoms significantly declined from enrolment (6.04  $\pm$  4.32) to 3 months (3.25  $\pm$  3.05) and 12 months (2.62  $\pm$  2.74;  $p < .0001$ ). Treatment-related AEs were reported by 38.7% (113/292) of women.

**Conclusion:** The real-world experience of women receiving NOMAC/E2 indicated very good treatment continuation, high satisfaction and significantly improved menstrual cycle-related symptoms.

### ARTICLE HISTORY

Received 20 July 2018  
Revised 5 October 2018  
Accepted 23 October 2018  
Published online 15 November 2018

### KEYWORDS



Contraception continuation; 17 $\beta$ -estradiol; BOLERO Study; hormonal contraception; menstrual cycle symptoms; natural estrogen; real world

### Introduction

Combined oral contraception (COC) continues to be a frequently selected contraceptive method among European women [1]. The evolution in COC formulations to improve safety and tolerability has included ethinylestradiol (EE) and progestin dose reductions, development of new progestins and varied dosing regimens [2]. More recently, COC based on oestradiol (E2), structurally identical to endogenous 17 $\beta$ -E2, has become available [3]. Nomegestrol acetate (NOMAC)/E2 (Zoely; Teva Italia, Milan, Italy), approved by the European Medicines Agency in 2011, is the first monophasic 24/4 day COC regimen to use 17 $\beta$ -E2. It has been shown that E2, micronised to improve bioavailability, has weak estrogenic effects and a mild metabolic impact on

estrogen-sensitive hepatic proteins [3]. NOMAC, derived from 19-norprogesterone with almost exclusive binding to the progesterone receptor, has been shown to be metabolically neutral with no androgenic, estrogenic or glucocorticoid activity and with moderate antiandrogenic activity [3].

The efficacy of NOMAC/E2, as well as good menstrual cycle control, with shorter and lighter withdrawal bleedings and absence of withdrawal bleeding for some women, has been demonstrated in randomised, open-label, multicentre trials that compared NOMAC/E2 with a drospirenone/EE 21/7 day regimen [4,5]. NOMAC/E2 has also been associated with reduced premenstrual and menstrual symptoms and menstrual cramping [6,7], as well as improved quality of life [7,8]. NOMAC/E2 contraceptive efficacy was maintained with less stringent back-up requirements following missed pills, likely

**CONTACT** Angelo Cagnacci  [angelo.cagnacci@uniud.it](mailto:angelo.cagnacci@uniud.it)  Clinica Ginecologica e Ostetrica, Azienda Sanitaria Universitaria Integrata di Udine, Piazzale Santa Maria della Misericordia 15, Udine, 33100, Italy

\*A complete list of members of the BOLERO Study Investigators is provided in the appendix.

© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

related to the long half-life of NOMAC (46 h) and the 24/4 day regimen of NOMAC/E2 [4,5]. Consistent with this finding, contraceptive protection is not reduced if the missed NOMAC/E2 active pill is taken <24 h late [9]. Further, compared with levonorgestrel/EE, NOMAC/E2 has demonstrated significantly less haemostatic impact (assessed via evaluation of coagulation and fibrinolysis markers), no alteration of carbohydrate metabolism (assessed using glucose tolerance and insulin resistance) and a neutral effect on lipid metabolism (assessed through levels of triglycerides and low- and high-density lipoprotein cholesterol) [10]. The potential for reduced haemostatic impact is noteworthy given the continued efforts to reduce the risk of venous thromboembolism that is moderately associated with COC treatment [10].

NOMAC/E2 may help address an ongoing need for COC formulations that support treatment continuation, given that concerns about the use of synthetic hormones and associated side effects are frequently reported by women as reasons for COC discontinuation [11,12]. Women have expressed a preference for COC based on natural estrogen, following contraceptive counselling, primarily because of fear of synthetic hormones or a desire for decreased bleeding associated with E2-based COC [13]. To address whether NOMAC/E2 meets these characteristics, the current study examined treatment continuation and satisfaction over 1 year among women receiving NOMAC/E2 for contraception in real-world clinical practice.

## Methods

### Study design and population

The 17 $\beta$ -Estradiol and Norgestrel Acetate (BOLERO) Study is an observational, non-interventional, prospective, multi-centre cohort study conducted in 17 centres in Italy. Eligible participants were premenopausal women aged 18–50 years, with or without prior COC use, who were prescribed NOMAC 2.5 mg/E2 1.5 mg for contraception during routine clinical practice. Contraceptive treatment selection and consent to study participation were independent decisions. Women received their prescription for NOMAC/E2  $\geq$  1 month and <3 months prior to study enrolment. Exclusion criteria included any condition that contraindicated use of COC and age  $\geq$  35 years in current smokers. Women were recruited over a 15 month period and were followed for a period of 12 months (13 treatment cycles). Study assessments were carried out at enrolment and at 3, 6 and 12 months. The end-of-study final evaluation was completed before 12 months if a woman discontinued study participation early.

The study was conducted in full conformance with the principles of the Declaration of Helsinki, and fully adhered to the Guideline for Good Clinical Practice, International Conference on Harmonization Tripartite Guideline and local laws. Independent ethics committees of the participating centres approved the study protocol; women provided informed consent prior to participation in the study.

### Assessments

The primary efficacy outcome was continuation of treatment, defined as the number of treatment cycles completed over 12 months and assessed using a daily diary.

Secondary outcomes included treatment satisfaction, menstrual cycle-related symptoms and libido. Treatment satisfaction was assessed with a 7 point scale ranging from 'very unsatisfactory' to 'very satisfactory' at 3, 6 and 12 months or at the final study visit. Additionally, treating physicians rated treatment satisfaction at 12 months or at the final study visit using the Clinical Global Impression (CGI) 7 point scale that ranged from 'very unsatisfactory' to 'very satisfactory'. Evaluation of menstrual cycle-related symptoms included headache, breast pain/tenderness, swelling (abdominal swelling and oedema), dysmenorrhoea and mood disturbance. Symptoms were assessed using 5 point scales ranging from 'absent' to 'serious', and the total symptom score was summed across the individual symptoms. The assessment of menstrual cycle-related symptoms at enrolment was retrospective: women were asked to assess symptoms related to their last three menstrual cycles prior to initiating NOMAC/E2. Additionally, treating physicians rated the degree of improvement in overall menstrual cycle-related characteristics and symptoms at 12 months or at the final study visit using the CGI 7 point scale that ranged from 'much worse' to 'much improved'. Level of libido was rated on a 5 point scale that ranged from 'very poor' to 'very satisfactory' at 3, 6 and 12 months or at the final study visit.

Safety was examined through reports of adverse events (AEs) from study enrolment to the final study visit. Treatment emergent AEs (TEAEs) and treatment-related AEs were assessed. Physicians rated AEs as unrelated (no reasonable possibility) or related (reasonable possibility) to treatment, and AE severity (mild/moderate/severe) and AE seriousness (yes/no). AEs were coded by MedDRA version 16.0 ([www.meddra.org](http://www.meddra.org)) and used preferred terms.

**Table 1.** Demographic and clinical characteristics of women receiving NOMAC/E2 ( $N = 298$ ).

Characteristic	Value
Age, years	29.2 $\pm$ 7.4
Age categories, years	
$\leq$ 25	102 (34.2)
26–30	87 (29.2)
31–35	53 (17.8)
36–40	24 (8.1)
>40	32 (10.7)
Race	
Asian	2 (0.7)
Black	2 (0.7)
Caucasian	287 (96.3)
Hispanic	3 (1.0)
Other	4 (1.3)
Smoking, yes	53 (17.8)
Marital status	
Single	206 (69.1)
Married	82 (27.5)
Divorced	10 (3.4)
Education	
High school	140 (47.0)
Secondary school	38 (12.8)
University	120 (40.3)
Work status	
Student	92 (30.9)
Employed	72 (24.2)
Housewife	20 (6.7)
Unemployed	24 (8.1)
Other	90 (30.2)
BMI, kg/m <sup>2</sup>	21.5 $\pm$ 3.1
Systolic blood pressure, mmHg	111.6 $\pm$ 10.3
Diastolic blood pressure, mmHg	69.1 $\pm$ 7.7

Values are expressed as mean  $\pm$  SD or  $n$  (%).

**Table 2.** Menstrual cycle and contraceptive method history of women receiving NOMAC/E2 ( $N = 298$ ).

Medical history	Value
Age at menarche, years	12.4 ± 1.4
Cycle type, regular	223 (74.8)
Mean menstruation duration, days	4.9 ± 1.6
Prior pregnancy, yes	80 (26.8)
Prior abortion, yes	44 (14.8)
Use of previous contraception, yes	240 (80.5)
Method of previous contraception <sup>a</sup>	
COC	169 (56.7)
Barrier contraception	107 (35.9)
Natural contraceptive method	32 (10.7)
Reason for discontinuation of previous COC ( $n = 169$ ) <sup>a</sup>	
No longer needed contraception (planning pregnancy or no partner)	34 (20.1)
Weight increase	27 (16.0)
Spotting	26 (15.4)
Headache	22 (13.0)
Reduced libido	10 (5.9)
Liquid retention/oedema	10 (5.9)
Poor compliance	9 (5.3)
Desired a different COC	7 (4.1)
Medical symptoms/physician recommendation	7 (4.1)
Acne	6 (3.6)
Vaginal dryness	5 (3.0)
Mood changes	3 (1.8)
Breast tension	2 (1.2)
Nausea	3 (1.8)
Poor efficacy	3 (1.8)
Desired different contraceptive method	2 (1.2)
Other <sup>b</sup>	15 (8.9)

Values are expressed as mean ± SD or  $n$  (%).

<sup>a</sup>Multiple responses allowed.

<sup>b</sup>Other reasons included: participant decision without further explanation ( $n = 6$ ), unknown ( $n = 6$ ), amenorrhoea ( $n = 1$ ), metrorrhagia ( $n = 1$ ) and dysmenorrhoea ( $n = 1$ ).

## Data analysis

The primary outcome of continuation of NOMAC/E2 treatment was assessed using Kaplan–Meier survival analysis and is reported as the discontinuation-free probability estimate at day 365 with 95% confidence intervals (CIs). Change in the menstrual cycle-related total symptom score was examined using general linear models for repeated measures with 95% CIs. This analysis used a univariate test for within-subject effects using mixed models (Proc Mixed; SAS Institute, Cary, NC, USA) to fit models with a variety of error covariance matrices and evaluate the patterns of covariance matrices (defined as type H covariances) to satisfy the Huynh–Feldt condition, by applying a sphericity test. Adjustment to numerator and denominator degrees of freedom was used to obtain an unbiased estimate of the effects. Treatment satisfaction, CGI physician ratings and libido were examined descriptively using percentages within response categories. AEs were summarised by the percentage of women experiencing any AE and by individual AEs. Analyses included all enrolled women and were completed using SAS version 9.2 or later (SAS Institute, Cary, NC, USA). Numerical data are expressed as mean ± standard deviation (SD). For all statistical analyses,  $p$ -values < .05 were considered significant.

## Results

A total of 298 women from 17 centres were enrolled (Tables 1 and 2). The mean age was  $29.2 \pm 7.4$  years, 82.2% (245/298) of women were non-smokers, 11.1% (33/298) were overweight (body mass index [BMI]  $25.0$ – $30.0$  kg/m<sup>2</sup>) and 1.7% (5/298) were moderately obese (BMI  $30.0$ – $35.0$  kg/m<sup>2</sup>). Previous contraception was reported by 80.5% (240/298) of women, including COC (56.7% [169/


298]), barrier contraception (35.9% [107/298]) and natural contraceptive methods (10.7% [32/298]). Mean time from NOMAC/E2 prescription to study enrolment was  $44.6 \pm 35.0$  days. Among the 298 enrolled women, no additional information was available for six women. Accordingly, all subsequent analyses were performed on 292 women. Examination of participant disposition showed that 200/292 women (68.5%) continued study participation through 12 months (Figure 1), and study completion was similar between women with prior COC use (69.5% [116/167] of women) and women with no prior COC use (67.2% [84/125]). Reasons for early discontinuation of study participation included those unrelated to treatment (17/292 [5.8%]), those related to treatment (51/292 [17.5%]) and those lost to follow-up (24/292 [8.2%]). Conservatively, women lost to follow-up were grouped with those with early discontinuation due to treatment.

## Treatment continuation


Kaplan–Meier analysis showed that the probability of NOMAC/E2 continuation from enrolment to day 365 was 73.7% (95% CI 68.0%, 78.5%; Figure 2). Among women with prior COC use before starting NOMAC/E2, the probability of treatment continuation to day 365 was 74.2% (95% CI 67.8%, 80.6%). Among women with no prior COC use, the probability of treatment continuation to day 365 was 70.7% (95% CI 61.5%, 78.1%).

## Treatment satisfaction, menstrual cycle-related symptoms and libido


Satisfaction with NOMAC/E2 increased from 56.9% (37/65) of women at the time of initial evaluation performed



**Figure 1.** Participant disposition. Reasons for discontinuation of NOMAC/E2 included treatment-related AEs, poor compliance, dissatisfaction and decision to change contraceptive method. Discontinuation of NOMAC/E2 that was not treatment-related included no longer needed contraception, scheduled surgery and desire for pregnancy.



**Figure 2.** Probability of treatment continuation for 12 months among women receiving NOMAC/E2. The Kaplan–Meier discontinuation-free probability estimate from enrolment to day 365 was 73.7% (95% CI 68.0%, 78.5%). Censored women ( $n = 217$ ) included treatment completers ( $n = 200$ ) and women who discontinued for reasons not related to treatment ( $n = 17$ ). Discontinuation events ( $n = 75$ ) included women who discontinued treatment due to treatment-related AEs, poor compliance, dissatisfaction or decision to change contraceptive method ( $n = 51$ ), and women lost to follow-up ( $n = 24$ ).



**Figure 3.** Treatment satisfaction among women receiving NOMAC/E2.

within 3 months of NOMAC/E2 use to 89.2% (58/65) of women at the final visit performed 12 months after initial evaluation (Figure 3). Among the 28 women dissatisfied at enrolment, 92.9% (26/28) were satisfied with treatment at the final visit; only 13.5% (5/37) of those satisfied at enrolment were dissatisfied at the final visit. Additionally, physician ratings of each woman's treatment satisfaction at 12 months showed unsatisfactory in 7.0% (14/200), indifferent in 9.0% (18/200) and satisfactory to very satisfactory in 84.0% (168/200).

Women reported a significant improvement in menstrual cycle-related symptoms ( $p < .0001$ ) during NOMAC/E2 treatment (Table 3). The menstrual cycle-related total symptom rating declined from  $6.04 \pm 4.32$  at enrolment to

**Table 3.** Change from enrolment in menstrual cycle-related symptoms of women receiving NOMAC/E2.

Variable	Total symptom score <sup>a</sup> Mean $\pm$ SD	Change from enrolment 95% CI
Women completing the study ( $n = 200$ )		
Enrolment	$6.04 \pm 4.32$	–
Month 3	$3.25 \pm 3.05$	–2.25, –3.40
Month 6	$2.96 \pm 3.13$	–2.47, –3.59
Month 12	$2.62 \pm 2.74$	–2.86, –3.98
Prior COC use ( $n = 116$ )		
Enrolment	$5.73 \pm 4.05$	–
Month 3	$3.13 \pm 3.08$	–1.91, –3.44
Month 6	$2.94 \pm 3.04$	–1.97, –3.43
Month 12	$2.45 \pm 2.80$	–2.53, –4.03
No prior COC use ( $n = 84$ )		
Enrolment	$6.47 \pm 4.67$	–
Month 3	$3.41 \pm 3.04$	–2.12, –3.93
Month 6	$3.00 \pm 3.25$	–2.59, –4.35
Month 12	$2.86 \pm 2.65$	–2.77, –4.46

<sup>a</sup>Mixed model for repeated measures of change from enrolment in total symptom score,  $p < .0001$ . Total symptom score is the sum of the ratings of the individual symptoms on a 5 point scale ranging from absent to serious for menstrual cycle-related headache, breast pain/tenderness, swelling, dysmenorrhoea and mood disturbance.

$3.25 \pm 3.05$  at 3 months of NOMAC/E2 treatment, and further declined to  $2.62 \pm 2.74$  at 12 months. Women with prior COC use before initiating NOMAC/E2 and women without prior COC use were similar in their report of menstrual cycle-related symptoms at enrolment and decline in symptoms over 12 months with NOMAC/E2 (Table 3). Physicians rated cycle characteristics and symptoms at 12 months as worsened in 20% (40/200), unchanged in 14.5% (29/200) and slightly to much improved in 65.5% (131/200) of women.






Figure 4. Libido among women receiving NOMAC/E2.

Table 4. Treatment-related AEs reported by  $\geq 2\%$  of women receiving NOMAC/E2 ( $N = 292$ ).

Treatment-related AE <sup>a</sup>	<i>n</i> (%)
Metrorrhagia <sup>b</sup>	39 (13.4)
Amenorrhoea	28 (9.6)
Headache	25 (8.6)
Drug withdrawal headache	1 (0.3)
Other headache/migraine	24 (8.2)
Abdominal distension	10 (3.4)
Breast discomfort or pain	8 (2.7)
Mood changes	7 (2.4)
Acne	6 (2.1)

<sup>a</sup>Individual participants can be included in more than one treatment-related AE category.

<sup>b</sup>The MedDRA preferred term metrorrhagia includes breakthrough bleeding and spotting.

Libido was not affected by NOMAC/E2 treatment. Unsatisfactory libido was reported by 14.7% of women at the enrolment visit and by 10.7% after a follow-up of 12 months (Figure 4).

## Safety

TEAEs were reported by 44.2% (129/292) of women; 38.7% (113/292) of women experienced AEs that were considered possibly treatment-related. The most common treatment-related AEs (reported by 2–13% of women) were metrorrhagia, amenorrhoea, headache, abdominal distension, breast discomfort, mood changes and acne (Table 4). Less than 2% of women reported weight gain ( $n = 4$ ; 1.4%) or decreased libido ( $n = 2$ ; 0.7%). Two serious AEs were reported, including primary mediastinal large B cell lymphoma, considered unrelated to treatment, and a pregnancy. The pregnancy occurred in a 22-year-old single woman with a BMI 24.2 kg/m<sup>2</sup>. She reported that her previous use of COC had been interrupted for headache. No information was available on her use of NOMAC/E2 or the pregnancy outcome.

Treatment discontinuation due to AEs occurred in 31/292 (10.6%) women. The AEs most commonly associated with treatment discontinuation were headache (drug withdrawal headache,  $n = 1$ ; other headache or migraine,  $n = 11$ ) and mood changes ( $n = 7$ ). Treatment discontinuation due to metrorrhagia occurred in 3/292 (1.0%) of women, suggesting that most women with metrorrhagia were experiencing breakthrough spotting or light bleeding.

## Discussion

### Findings and interpretation

Efficacious and tolerable COC that supports treatment continuation, satisfaction and adherence is essential to prevent COC discontinuation and potential subsequent use of less effective contraceptive methods [11], and further reduce the number of unplanned pregnancies. NOMAC/E2 may be an especially good match for women who prefer COC based on natural estrogen. In the current study, women who selected NOMAC/E2 for contraception during routine clinical practice showed high probability of treatment continuation from study enrolment to 12 months.

### Differences and similarities in relation to other studies

Most women reported satisfaction with NOMAC/E2 throughout the study. This was consistent with the significant improvement in menstrual cycle-related symptoms reported by women and their physicians. The significant improvement in menstrual cycle-related symptoms, including headache, breast pain/tenderness, swelling, dysmenorrhoea and mood disturbance, observed at 3 months and with continued improvement to 12 months, is consistent with previous studies examining NOMAC/E2 [6,7]. The high NOMAC/E2 continuation rate is also consistent with the low frequency of AEs resulting in treatment discontinuation. The report of satisfactory libido by most women in the current study is in line with the report of improved sexual function among women who chose to switch to NOMAC/E2 from another COC due to dissatisfaction with sexual desire during their previous treatment [14]. The amenorrhoea experienced by some women is similar to findings from previous NOMAC/E2 studies and is likely related to the long half-life of NOMAC and 24/4 day NOMAC/E2 regimen [4,5].

Concern about side effects is frequently reported by women as their primary reason for COC dissatisfaction and discontinuation, including concern about side effects related to EE and consideration of switching contraception to reduce exposure to hormones [11,12,15–17]. In a real-world clinical practice study of women in Spain, 21.1% of women discontinued COC use for treatment-related reasons, including poor cycle control, side effects, method failure and 'other' [18]. In our study of women receiving NOMAC/E2 in routine clinical practice, treatment-related reasons for discontinuation, including AEs or other reasons, was lower at 17.5% of women. Non-treatment-related discontinuation in our study, in 5.8% of women, was similar to a real-world clinical practice study of COC continuation in Spain that reported 6.6% (including women with pregnancy desire and change in sexual habits), whereas our participants lost to follow-up were fewer (8.2% vs 19.3%) [18]. The continuation rate of NOMAC/E2 in our study appears to be comparable to, or higher than, COC continuation rates reported in other population-based cohorts or real-world studies [16–19].

### Strengths and weaknesses of the study

Strengths of this study include the real-world examination of a large sample of women receiving NOMAC/E2 for

contraception during routine clinical practice. Real-world evaluations of contraceptive outcomes complement the findings of controlled clinical trials because clinical trial participants are often specially selected and may not be representative of the general population of COC users, and clinical trial methods such as free contraception and regular participant follow-up may not accurately reflect COC continuation in real life [19,20]. In our study, women received their prescription for NOMAC/E2 during routine clinical care and study participants independently answered questions about their experience with NOMAC/E2. Because participants were not encouraged to continue NOMAC/E2 or provided with any financial or other support, the effect of study participation on treatment continuation was probably minimal.

Real-world prospective observational studies of clinical practice outcomes also complement findings from retrospective health claims database studies. Database studies provide important information on the use of contraceptive treatment across large populations of women [21]; however, many relevant variables, such as change in menstrual cycle-related symptoms, are not captured in these databases. Such clinical information, necessary to understanding the reasons underlying continuation of COC, as well as potential targets for contraceptive counselling, can be gathered in real-world observational studies.

The current observational study excluded women receiving other COC formulations, which prevented direct comparisons among types of COC. The study findings should be considered preliminary and warrant further comparative investigation of COC continuation and satisfaction among women who select NOMAC/E2 vs EE-based COC.

## Conclusion

NOMAC/E2 is the first monophasic 24/4 day COC regimen based on E2, which is structurally identical to the endogenous 17 $\beta$ -E2 that is naturally produced by the ovaries. Previous studies have indicated a preference for COC based on natural estrogen among some women, and improved quality of life among women who switched to COC based on natural estrogen. In our study, the real-world experience of women who were prescribed NOMAC/E2 during routine clinical practice indicated very good treatment continuation and high satisfaction with treatment through 12 months. The non-contraceptive benefits of NOMAC/E2 included significantly improved menstrual cycle-related symptoms of headache, breast pain/tenderness, swelling, dysmenorrhoea and mood disturbance. Our findings provide further evidence that NOMAC/E2 COC meets contraceptive and non-contraceptive needs and supports treatment continuation among women seeking contraception based on natural estrogen.

## Acknowledgements

The authors wish to thank Lynanne McGuire, of MedVal Scientific Information Services, for providing medical writing and editorial assistance. This manuscript was prepared according to the International Society for Medical Publication Professionals' 'Good Publication Practice for Communicating Company-Sponsored Medical Research: the GPP3 Guidelines'.

## Disclosure statement

ACa has served as a speaker for Teva Italia, MSD, Gedeon Richter and Bayer. MV is a consultant for Bayer and Gedeon Richter. GB is an employee of Teva Italia and previously worked for MSD. CBa, MN, ACi, CBe, LC, VDL, EC and AV report no conflicts of interest.

## Funding

Medical writing assistance was provided by MedVal Scientific Information Services (Princeton, NJ, USA) and was funded by Teva Branded Pharmaceutical Products R&D (Frazer, PA, USA). This study was supported by Teva Italia, which provided a full review of the article.

## References

- [1] Egarter C, Frey Tirri B, Bitzer J, et al. Women's perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. *BMC Women's Health*. 2013;13.
- [2] Burkman R, Bell C, Serfaty D. The evolution of combined oral contraception: improving the risk-to-benefit ratio. *Contraception*. 2011;84:19–34.
- [3] Chabbert-Buffet N, Gerris J, Jamin C, et al. Toward a new concept of 'natural balance' in oral estrogen-progestin contraception. *Gynecol Endocrinol*. 2013;29:891–896.
- [4] Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing norgestrel acetate and 17 $\beta$ -estradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. *Eur J Contracept Reprod Health Care*. 2011;16:430–443.
- [5] Westhoff C, Kaunitz AM, Korver T, et al. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing norgestrel acetate and 17 $\beta$ -estradiol: a randomized controlled trial. *Obstet Gynecol*. 2012;119:989–999.
- [6] Witjes H, Creinin MD, Sundstrom-Poromaa I, et al. Comparative analysis of the effects of norgestrel acetate/17 $\beta$ -estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea. *Eur J Contracept Reprod Health Care*. 2015;20:296–307.
- [7] Grandi G, Napolitano A, Xholli A, et al. Effect of oral contraceptives containing estradiol and norgestrel acetate or ethinylestradiol and chlormadinone acetate on primary dysmenorrhea. *Gynecol Endocrinol*. 2015;31:774–778.
- [8] Lete I, de la Viuda E, Perez-Campos E, et al. Effect on quality of life of switching to combined oral contraception based on natural estrogen: an observational, multicentre, prospective phase IV study (ZOCAL Study). *Eur J Contracept Reprod Health Care*. 2016;21:276–284.
- [9] European Medicines Agency. Zoely 2.5 mg/1.5 mg film-coated tablets. Summary of product characteristics; 2016 [accessed 2016 May 17]. Available from: [www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/001213/WC500115831.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001213/WC500115831.pdf).
- [10] Lete I, Chabbert-Buffet N, Jamin C, et al. Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: a literature review. *Eur J Contracept Reprod Health Care*. 2015;20:329–343.
- [11] Huber LR, Hogue CJ, Stein AD, et al. Contraceptive use and discontinuation: findings from the contraceptive history, initiation, and choice study. *Am J Obstet Gynecol*. 2006;194:1290–1295.
- [12] Wigginton B, Harris ML, Loxton D, et al. A qualitative analysis of women's explanations for changing contraception: the importance of non-contraceptive effects. *J Fam Plann Reprod Health Care*. 2016;42:256–262.
- [13] Lete I, Barbado N, Ugarte L, et al. A cross-sectional study of the choice of oral estrogen contraceptives in women seeking contraceptive counseling: what type of pill do women prefer after being counseled? *Gynecol Obstet*. 2015;5:100321.
- [14] Caruso S, Cianci S, Cariola M, et al. Improvement of low sexual desire due to antiandrogenic combined oral contraceptives

- after switching to an oral contraceptive containing 17 $\beta$ -estradiol. *J Women's Health (Larchmt)*. 2017;26:728–734.
- [15] Hooper DJ. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. *Clin Drug Investig*. 2010;30:749–763.
- [16] Johnson S, Pion C, Jennings V. Current methods and attitudes of women towards contraception in Europe and America. *Reprod Health* 2013;10.
- [17] Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. *Contraception*. 2007;76:267–272.
- [18] Lete I, Perez-Campos E, Correa M, et al. Continuation rate of combined hormonal contraception: a prospective multicenter study. *J Women's Health (Larchmt)*. 2012;21:490–495.
- [19] Moreau C, Bouyer J, Bajos N, et al. Frequency of discontinuation of contraceptive use: results from a French population-based cohort. *Hum Reprod*. 2009;24:1387–1392.
- [20] Van Vliet HA, Grimes DA, Lopez LM, et al. Triphasic versus monophasic oral contraceptives for contraception. *Cochrane Database Syst Rev*. 2011;11:CD003553.
- [21] Murphy PA, Brixner D. Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database. *Contraception*. 2008;77:257–263.
- Prof. Antonio Cianci, MD, Dipartimento Chirurgia Generale e Specialità Medico Chirurgiche, Azienda Ospedaliero Universitaria Policlinico-Vittorio Emanuele, Catania, Italy
- Prof. Ettore Cicinelli, MD, 2° Unità Operativa di Ginecologia ed Ostetricia, Dipartimento di Medicina e Oncologia (DIMO), Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy
- Prof. Vincenzo De Leo, MD, Dipartimento di Medicina Molecolare e dello Sviluppo, Azienda Ospedaliera Universitaria Senese, Siena, Italy
- Dr Francesco De Seta, MD, IRCCS Materno Infantile Burlo Garofolo, Trieste, Italy
- Prof. Costantino Di Carlo, MD, Azienda Ospedaliera Universitaria Federico II, Naples, Italy
- Prof. Lorenza Driul, MD, Azienda Ospedaliera Universitario S. Maria della Misericordia di Udine, Udine, Italy
- Dr Manuela Farris, MD, PhD, La Sapienza Università di Roma, Rome, Italy
- Prof. Simone Ferrero, MD, Università degli Studi di Genova, Genoa, Italy
- Dr Franca Fruzzetti, MD, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
- Dr Antonio Maiorana, MD, P.O. Civico e Benfratelli di Palermo, Palermo, Italy
- Prof. Diego Marchesoni, MD, Azienda Ospedaliera Universitario S. Maria della Misericordia di Udine, Udine, Italy
- Prof. Carmine Nappi, MD, Azienda Ospedaliera Universitaria Federico II, Naples, Italy
- Prof. Rossella Nappi, MD, Fondazione IRCCS, Policlinico San Matteo, Pavia, Italy
- Dr Manuela Neri, MD, Clinica Ostetrica e Ginecologica, Dipartimento di Scienze Chirurgiche, Università degli Studi di Cagliari, Azienda Ospedaliero Universitaria di Cagliari, Policlinico Universitario Duilio Casula, Monserrato, Cagliari, Italy
- Dr Francesca Pampaloni, MD, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
- Prof. Anna Maria Paoletti, MD, Azienda Ospedaliero Universitaria di Cagliari, Policlinico Universitario Duilio Casula, Monserrato, Cagliari, Italy
- Prof. Felice Petraglia, MD, Azienda Ospedaliera Universitaria Senese, Siena, Italy
- Prof. Pasquale Scagliola, MD, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
- Prof. Pierluigi Venturini, MD, Università degli Studi di Genova, Genoa, Italy
- Prof. Michele Vignali, MD, PhD, Dipartimento di Scienze Biomedicine per la Salute, Università degli Studi di Milano, P.O. Macedonio Melloni, Milan, Italy
- Prof. Annibale Volpe, MD, Facoltà di Medicina e Chirurgia Materno-Infantili e dell'Adulto, Università degli Studi di Modena e Reggio Emilia, Modena, Italy

## Appendix

### **BOLERO Study Investigators**

Dr Luigi Alio, MD, P.O. Civico e Benfratelli di Palermo, Palermo, Italy

Dr Carlo Bastianelli, MD, Dipartimento di Scienze Ostetriche e Ginecologiche e Scienze Urologiche, La Sapienza Università di Roma, Rome, Italy

Prof. Chiara Benedetto, MD, PhD, Dipartimento di Scienze Chirurgiche, Università degli Studi di Torino, Turin, Italy

Dr Giuseppe Borrelli, MD, Teva Italia Srl, Assago, Milan, Italy

Dr Sandra Bucciattini, MD, Azienda Ospedaliero Universitaria Careggi, Florence, Italy

Prof. Angelo Cagnacci, MD, PhD, Clinica Ginecologica e Ostetrica, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy

Dr Luana Calanni, MD, Clinica Ostetrica e Ginecologia, Ospedale Policlinico San Martino, Genoa, Italy

Prof. Salvatore Caruso, MD, Dipartimento Chirurgia Generale e Specialità Medico Chirurgiche, Azienda Ospedaliero Universitaria Policlinico-Vittorio Emanuele, Catania, Italy

Prof. Irene Cetin, MD, Azienda Ospedaliera-Polo Universitario, Milan, Italy